Strategy will focus on becoming the dominant
mid-market PBM, unlocking the value of pharmacists and revitalizing
Rite Aid’s retail and digital experience
Narrows Adjusted EBITDA Outlook for Fiscal
2020
Provides Fiscal Year 2021 Guidance
Provides Long-Term Financial Outlook
Rite Aid Corporation (NYSE: RAD) (“Rite Aid” or the “Company”)
announced that management will outline the Company’s corporate
strategy and growth plan at its Analyst Day held via webcast today.
The Company will provide details on how its strategic initiatives
are designed to drive revenue and Adjusted EBITDA growth, as well
as reduce the Company’s leverage ratio.
“Rite Aid is a business in the midst of a turnaround and it is
time for a radical change – our RxEvolution,” said Heyward Donigan,
president and chief executive officer, Rite Aid. “This is not
business as usual at Rite Aid. We have the unique opportunity to
serve a growing customer base and strengthen the power of our
iconic brand. We are doubling down on our pharmacy business. We are
renewing our commitment to leverage the power of our trusted
pharmacists across our retail and pharmacy services business to
deliver on the promise of real consumer engagement. Our pharmacists
are among the most accessible and trusted health care professionals
in America. This means we really can help our customers not just
get healthy, but get thriving.”
Donigan continued, “We have already made significant progress
and have built a strong foundation to deliver on our turnaround.
Over the past seven months, we have made key changes to our
management team, reduced our leverage ratio and instilled an acute
focus on execution and innovation. We are in the process of
profoundly changing and modernizing the technology platforms that
power our company, with a relentless focus on customer experience
and design. We are also executing well on our prescription and
clinical services growth. Rite Aid is now better positioned to
execute on our key initiatives to grow our revenue, achieve
efficiencies across our business, drive Adjusted EBITDA growth and
generate cash flow to invest in our business and reduce our
debt.”
Rite Aid’s strategy for evolving the business and revitalizing
the brand will focus on innovation in three areas:
- Becoming the dominant mid-market PBM: Rite Aid’s
pharmacy benefits and services company, EnvisionRxOptions, includes
multiple PBMs, technology and claims adjudication software, mail
delivery and specialty pharmacy services, network and rebate
administration, as well as prescription discount programs and
Medicare Part D insurance for individuals and groups. With a
stronger, integrated offering, this business (soon to be rebranded
as Elixir) will be well positioned with mid-market employer groups
and regional health plans. Additionally, given the affiliation with
Rite Aid’s stores, EnvisionRxOptions has the opportunity to improve
its competitive positioning and deliver exceptional retail and mail
order pharmacy service while improving clinical outcomes.
EnvisionRxOptions is now the only payor-agnostic PBM with a retail
pharmacy footprint. Poised for strong growth and improved profits,
this unique PBM offering represents the largest enterprise value
creation opportunity for Rite Aid.
- Unlocking the value of Rite Aid’s pharmacists: Rite Aid
is innovating across all of its retail and mail-order pharmacy
channels, including its PBM and suite of pharmacy service
solutions. These innovations go beyond just filling prescriptions
to offering an array of over-the-counter, clinical and holistic
health and wellness solutions – focused on helping customers
thrive. Rite Aid’s more than 6,400 pharmacists will be whole-being
health advocates, who practice at the top of their license. The
Company’s pharmacists will go beyond their traditional role into an
expanded role, in which they are encouraging a holistic approach to
health. Rite Aid is leveraging its associates to engage with Lean
tools and develop new workflows and technologies to free up its
pharmacists’ time. Additionally, Rite Aid is launching its new
Pharmacy of the Future, which moves the Company’s pharmacists
physically closer to the customer. These new workflows, tools and
store design will allow pharmacists to engage more meaningfully
with Rite Aid customers.
- Revitalizing Rite Aid’s retail and digital experience:
As consumers increasingly focus on self-care, they seek to strike
the perfect balance between traditional health and holistic
wellness. Rite Aid will be a whole-being health destination that
treats mind, body and spirit. To introduce new generations to its
iconic brand, Rite Aid is elevating its in-store experience,
increasing personalized digital engagement, and refreshing
merchandise to include a wide assortment of products with
attributes that resonate with Millennial and Gen X consumers. Rite
Aid will be re-branding with a new logo to signal this bold change
in pharmacy and retail. Later this year, Rite Aid will introduce
its Store of the Future, which will be a trusted whole-family
wellness destination that helps consumers on the journey of care
for parents, children and pets.
Rite Aid believes its RxEvolution will deliver meaningful value
with a disciplined approach to investments and a focus on
initiatives that will generate the greatest return.
Outlook for Fiscal 2020
The Company is narrowing its Fiscal 2020 outlook for Adjusted
EBITDA and Revenues and adjusting its outlook for Capital
Expenditures.
Rite Aid Corporation expects revenues to be between $21.9
billion and $21.925 billion in fiscal 2020 with same-store sales
expected to range from an increase of 1.0 percent to an increase of
1.1 percent over fiscal 2019.
Adjusted EBITDA is expected to be between $530.0 million
and $535.0 million.
Capital expenditures are expected to be approximately
$215.0 million.
Outlook for Fiscal 2021
The Company is providing the following outlook for fiscal year
2021:
Revenue is expected to be between $22.5 billion and $22.9
billion.
- Retail Pharmacy Segment: Same-store sales are expected
to be in the range of an increase of 1.5 percent to an increase of
2.5 percent.
- Pharmacy Services Segment: Revenue is expected to be
between $6.75 billion and $6.85 billion (net of any intercompany
revenues to Rite Aid retail).
Net loss is expected to be between $91.0 million and
$119.0 million.
Adjusted EBITDA is expected to be between $500.0 million
and $540.0 million.
Adjusted net (loss) income per share is expected to be
between a loss of $0.22 per share and income of $0.19 per
share.
Cash flow from operations is expected to be between
$400.0 million and $450.0 million.
Capital Expenditures are expected to be approximately
$350.0 million.
Rite Aid also expects to incur restructuring charges of
approximately $60.0 million in Fiscal 2021, which will not be
included in Adjusted EBITDA. These charges include costs to
relaunch the brand and to transition out of certain merchandise
lines.
Long-Term Financial Outlook
Based on the Company’s strategic initiatives, Rite Aid is
providing the following financial targets by fiscal year 2023:
- Pharmacy benefits and services revenue with high-single
to low-double digit growth
- Same-store scripts with mid-single digit growth
- Front End revenue with low-single digit growth
- Leverage ratio of approximately 4.0x
Analyst Day Webcast
The Analyst Day presentation will begin today, March 16, 2020 at
9:00 a.m. ET. The simultaneous, live webcast will be available on
the Investor Relations section of Rite Aid’s website at:
https://www.riteaid.com/corporate/investor-relations/presentations.
About Rite Aid Corporation
Rite Aid Corporation is on the front lines of delivering health
care services and retail products to over 1.6 million Americans
daily. Our pharmacists are uniquely positioned to engage with
customers and improve their health outcomes. We provide an array of
whole being health products and services for the entire family
through over 2,400 retail pharmacy locations across 18 states.
Through EnvisionRxOptions, we provide pharmacy benefits and
services to approximately 4 million members nationwide. For more
information, www.riteaid.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this release that are not historical, are
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such statements include, but are not limited to, statements
regarding Rite Aid's outlook and guidance for fiscals 2020 and
2021; Rite Aid's competitive position and ability to realize its
growth initiatives and operating efficiencies; the implementation
and success of our new business strategy and various initiatives
and objectives, including (i) improving our PBM business, (ii)
redefining the role of our pharmacists, and (iii) updating our
retail and digital experience; and any assumptions underlying any
of the foregoing. Words such as "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"predict," "project," "should," and "will" and variations of such
words and similar expressions are intended to identify such
forward-looking statements.
These forward-looking statements are not guarantees of future
performance and involve risks, assumptions and uncertainties,
including, but not limited to: our ability to successfully
implement our new business strategy and improve the operating
performance of our stores; our high level of indebtedness and our
ability to satisfy our obligations and the other covenants
contained in our debt agreements; general competitive, economic,
industry, market, political (including healthcare reform), and
regulatory conditions, including disruptions resulting from
pandemics or epidemics (such as the coronavirus), as well as
factors specific to the markets in which we operate; the impact of
private and public third-party payers continued reduction in
prescription drug reimbursements and efforts to encourage mail
order ;our ability to manage expenses and our investments in
working capital; our ability to achieve the benefits of our efforts
to reduce the costs of our generic and other drugs; outcomes of
legal and regulatory matters; our ability to partner and have
relationships with health plans and health systems; risks related
to the pending sale of the remaining Rite Aid distribution center
and related assets to Walgreens Boots Alliance, Inc. (“WBA”),
including the possibility that the transaction may not close; and
the continued integration of our new senior management team and our
ability to realize the benefits from our organizational
restructuring.
These and other risks, assumptions and uncertainties are more
fully described in Item 1A (Risk Factors) of our most recent Annual
Report on Form 10-K and in other documents that we file or furnish
with the Securities and Exchange Commission, which you are
encouraged to read.
Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results
may vary materially from those indicated or anticipated by such
forward-looking statements. Accordingly, you are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date they are made. Rite Aid expressly
disclaims any current intention to update publicly any
forward-looking statement after the distribution of this release,
whether as a result of new information, future events, changes in
assumptions or otherwise.
Reconciliation of Non-GAAP Financial Measures
Rite Aid separately reports financial results on the basis of
Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted
Share and Adjusted EBITDA which are non-GAAP financial measures.
See the attached tables for a reconciliation of Adjusted Net Income
(Loss), Adjusted Net Income (Loss) per Diluted Share and Adjusted
EBITDA to net income (loss), and net income (loss) per diluted
share, which are the most directly comparable GAAP financial
measures. Adjusted Net Income (Loss) and Adjusted Net Income (Loss)
per Diluted Share exclude amortization expense, merger and
acquisition-related costs, non-recurring litigation settlement,
gains and losses on debt retirements, LIFO adjustments, goodwill
and intangible asset impairment charges, restructuring-related
costs and the WBA merger termination fee. The current calculations
of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per
Diluted Share reflect a modification made in the second quarter of
fiscal 2019 to add back all amortization expenses rather than the
amortization of EnvisionRx intangible assets only. Adjusted EBITDA
is defined as net income (loss) excluding the impact of income
taxes, interest expense, depreciation and amortization, LIFO
adjustments, charges or credits for facility closing and
impairment, goodwill and intangible asset impairment charges,
inventory write-downs related to store closings, gains or losses on
debt retirements, the WBA merger termination fee, and other items
(including stock-based compensation expense, merger and
acquisition-related costs, non-recurring litigation settlement,
severance, restructuring-related costs and costs related to
facility closures and gain or loss on sale of assets). The current
calculation of Adjusted EBITDA reflects a modification made in the
second quarter of fiscal 2019 to eliminate the add back of revenue
deferrals related to our customer loyalty program and to present
amounts previously included within other as separate reconciling
items. We further note that the add back of LIFO (credit) charge
when calculating Adjusted EBITDA, Adjusted Net Income (Loss) and
Adjusted Net Income (Loss) per Diluted Share removes the entire
impact of LIFO (credits) charges, and effectively reflects Rite
Aid's results as if the company was on a FIFO inventory basis.
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS
GUIDANCE TO ADJUSTED EBITDA GUIDANCE
YEAR ENDING FEBRUARY 29, 2020
(In thousands)
(unaudited)
Guidance Range
Low
High
Total Revenues
$
21,900,000
$
21,925,000
Same store sales
1.00
%
1.10
%
Gross Capital Expenditures
$
215,000
$
215,000
Reconciliation of net loss to adjusted EBITDA: Net
loss
$
(189,000
)
$
(184,000
)
Adjustments: Interest expense
235,000
235,000
Income tax expense
40,000
40,000
Depreciation and amortization
330,000
330,000
LIFO charge
10,000
10,000
Lease termination and impairment charges
35,000
35,000
Gain on debt retirements, net
(56,000
)
(56,000
)
Restructuring-related costs
100,000
100,000
Other
25,000
25,000
Adjusted EBITDA
$
530,000
$
535,000
Guidance for Total Revenues, Same store sales, Gross Capital
Expenditures and Adjusted EBITDA has been updated. Guidance for Net
Loss is neither being confirmed or updated, as the Company is still
in the year end closing process. Some of the reconciling items
between Net Loss and Adjusted EBITDA, including those related to
income tax expense and LIFO charge, could differ from the
previously issued guidance shown in this table, and such
differences could be material. Net loss is shown above for
illustrative purposes only and in order to show how the Company is
calculating its updated Adjusted EBITDA guidance. You should not
place undue reliance on the Net Loss guidance above.
RITE AID CORPORATION AND
SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS
GUIDANCE TO ADJUSTED EBITDA GUIDANCE
YEAR ENDING FEBRUARY 27, 2021
(In thousands)
(unaudited)
Guidance Range
Low
High
Total Revenues
$
22,500,000
$
22,900,000
PBM Revenues
$
6,750,000
$
6,850,000
Same store sales
1.50
%
2.50
%
Gross Capital Expenditures
$
350,000
$
350,000
Reconciliation of net loss to adjusted EBITDA: Net
loss
$
(119,000
)
$
(91,000
)
Adjustments: Interest expense
215,000
215,000
Income tax expense
3,000
15,000
Depreciation and amortization
317,000
317,000
LIFO credit
(35,000
)
(35,000
)
Lease termination and impairment charges
41,000
41,000
Restructuring-related costs
60,000
60,000
Other
18,000
18,000
Adjusted EBITDA
$
500,000
$
540,000
RITE AID CORPORATION AND
SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS
GUIDANCE TO ADJUSTED NET (LOSS) INCOME GUIDANCE
YEAR ENDING FEBRUARY 27, 2021
(In thousands)
(unaudited)
Guidance Range
Low
High
Net loss
$
(119,000
)
$
(91,000
)
Add back - income tax expense
3,000
15,000
Loss before income taxes
(116,000
)
(76,000
)
Adjustments: Amortization expense
64,000
64,000
LIFO credit
(35,000
)
(35,000
)
Restructuring-related costs
60,000
60,000
Adjusted (loss) income before adjusted income taxes
(27,000
)
13,000
Adjusted income tax (benefit) expense
(15,000
)
3,000
Adjusted net (loss) income
$
(12,000
)
$
10,000
Diluted adjusted net (loss) income per share
$
(0.22
)
$
0.19
RITE AID CORPORATION AND
SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF ADJUSTED EBITDA
GUIDANCE TO FREE CASH FLOW
GUIDANCE
YEAR ENDING FEBRUARY 27, 2021
(In thousands)
(unaudited)
Guidance Range
Low
High
Adjusted EBITDA
$
500,000
$
540,000
Cash interest expense
(210,000
)
(210,000
)
Restructuring-related costs
(60,000
)
(60,000
)
Closed store rent
(30,000
)
(30,000
)
Working capital benefit
200,000
210,000
Cash flow from operations
400,000
450,000
Gross capital expenditures
(350,000
)
(350,000
)
Free cash flow
$
50,000
$
100,000
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200316005417/en/
Media: Chris Savarese 717-975-5718
Christopher.Savarese@riteaid.com
Investors: Byron Purcell 717-975-5809 investor@riteaid.com
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Apr 2023 to Apr 2024